Three months later, Lieping Chen group identified SIGLEC15 as a critical immune suppressor and its expression was mutually exclusive to PDL1, which implicated its potential therapeutic value in cancer patients especially for those who failed to response to anti-PDL1 therapy [20]. This evidence concerns the gene SIGLEC15 and cancer.